Can a new sensor track blood sugar with pinpoint accuracy?

NCT ID NCT07745244

Recruiting now Diagnosis Sponsor: SiBionics, Co, Ltd Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial evaluates a new continuous glucose monitoring (CGM) system in adults with type 1 diabetes. Participants will wear the sensor for 14 days while their blood sugar is measured against standard lab tests to see how accurate and safe the device is across different glucose levels. The goal is to determine if this CGM can reliably help people manage their diabetes in real time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GS3 continuous glucose monitoring (CGM) system
What this could lead to: If successful, this could provide a more accurate and safer way for people with type 1 diabetes to track their blood sugar in real time, potentially improving daily management and reducing complications.
What could go wrong: This is a small, early-stage study focused on device accuracy and safety, not on long-term health outcomes. The device may not perform consistently across all glucose ranges, and there is a risk of skin irritation or other device-related effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CGM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital primary megaureter type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CGM T1D TYPE1DIABETES

Contacts and locations

Locations

Zibo Central Hospital
RECRUITING

Zibo, Shandong, 255100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.